Regorafenib tablets 40mg/tablet, 28 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Bleeding: Serious or life-threatening bleeding should be permanently discontinued from LuciRegor.
• Skin toxicity: interrupt, reduce or discontinue LuciRegor depending on the severity and duration of skin toxicity.
• Blood Pressure: temporarily or permanently discontinue LuciRegor for severe or uncontrollable Blood Pressure.
• Cardiac ischemia and infarction: For new or acute cardiac ischemia/infarction, interrupt LuciRegor and resume only after resolution of the acute ischemic event.
• Reversible posterior leukoencephalopathy syndrome (RPLS): discontinuation of LuciRegor.
• Gastrointestinal perforation or fistula: Discontinue LuciRegor.
• Wound healing complications: Discontinue use of LuciRegor prior to surgery. Patients with open wounds should discontinue use.
• Embryo-fetal toxicity: May cause harm to the fetus. Inform the woman of the potential risks of the fetus.

Medication risks

Adverse Reactions
The most common adverse effects (≥ 30%) are fatigue/fatigue, decreased appetite and food intake, hand-foot skin response (HFSR) [palmoplantar paresthesia (PPE)], diarrhea, mucositis, weight loss, infection, Blood Pressure, and pronunciation disorders.